Extended Data Fig. 9|. 7-DHC promotes metastasis.

a, Levels of 7-DHC in B16F10 treated with 7-DHC (25 μM) for 24 h. b, Cell viability of B16F10 with treatment of RSL3 for 6–8 h following pretreatment of 7-DHC (25 μM) for 24 h. n=2 biological replicates. c, d, Image (c) and quantification (d) of B16F10 metastatic tumours in lungs with cells pretreated 7-DHC (25 μM) for 24 h. n=8 in each group. e, The protein level of Dhcr7 in sgNC and sgDhcr7 B16F10. f, Cell viability of sgNC and sgDhcr7 B16F10 treated with RSL3 for 6–8 h. n=2 biological replicates. g, Levels of 7-DHC in sgNC and sgDhcr7 B16F10. h, i, Image (h) and quantification (i) of sgNC and sgDhcr7 B16F10 metastatic tumours. n=8 in each group. j, k, Tumour volume (j) and tumour weight (k) of sgNC and sgDhcr7 B16F10 subcutaneous tumour. n=7 in each group,. l, Cell viability of sgNC and sgDhcr7 B16F10 treated with RSL3 for 10–12 h following pretreatment of TASIN-30 (10 μM) for 24 h. m, Levels of 7-DHC in sgNC and sgDhcr7 B16F10 treated with TASIN-30 (10 μM) for 24 h. n, o, Image (n) and quantification (o) of metastatic tumours of sgNC and sgDhcr7 B16F10 pretreated TASIN-30 (10 μM) for 24h. n=8 in each group. p, q, Image (p) and quantification (q) of metastatic tumours of B16F10 in mice pre-injected with vehicle or AY9944 (25 mg/kg) via i.p. once daily for four times prior to i.v. of B16F10. n=9 in each group. For a-q, data are representative of two independent experiments. Data are mean ± s.d. of n=3 biological replicates (a, g, i, m) for cell experiments and mean ± s.e.m for animal experiments, statistical analysis was performed using unpaired two-tailed t-test (a, d, g, i, k and q) or two-way ANOVA (m and o); **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, not significant.